In two phase @ studies ( AMAGINE-@ and AMAGINE-@ ) , patients with moderate-to-severe psoriasis were randomly assigned to receive brodalumab ( @ mg or @ mg every @ weeks ) , ustekinumab ( @ mg for patients with a body weight @ kg and @ mg for patients > @ kg ) , or placebo .